The Behavioral Economist
Behavioral finance, growth, small-cap, fund holdings

Verastem: Cancer May Have Met Its Match

Investors with a practical understanding of the biotechnology sector share an extraordinary opportunity; the chance to invest in the future. Granted, all investments are essentially an investment into the "future", but biotech takes that cliché and turns it into a tangible investment option. This is especially so in the case of small-cap, clinical stage companies, who have yet to see innovation transform into commercialization. For those companies, it is the prospect of bringing a product to market that keeps them going, and it is the likelihood of that happening that keeps investors on board. It is a delicate balance, and it is even further complicated by the very nature of the sector.

Clinical stage biotech's are not "normal" investments....

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
IDEA GENERATORXExclusive access to 10 PRO ideas every day
INVESTING IDEAS LIBRARYXExclusive access to PRO library of more than 15,000 ideas
SECTOR EXPERT NETWORKXExclusive access to all sector experts for direct consultation
PERFORMANCE TRACKINGXTrack performance of all PRO stock ideas
PROFESSIONAL TOOLSXProfessional Idea Filters to zero-in based on industry, market cap and more
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO."Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else."Patrick Rice, Mainstay Capital Management
You may cancel at any time for any reason, and receive a prompt refund for membership on months paid and not used (max. 6 months). Details